Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
, 40 (6), 2051-65

Use of Cardioselective β-Blockers in Patients With Chronic Obstructive Pulmonary Disease: A Meta-Analysis of Randomized, Placebo-Controlled, Blinded Trials

Affiliations
Meta-Analysis

Use of Cardioselective β-Blockers in Patients With Chronic Obstructive Pulmonary Disease: A Meta-Analysis of Randomized, Placebo-Controlled, Blinded Trials

Y Ni et al. J Int Med Res.

Abstract

Objective: To assess the effect of cardioselective β-blockers on pulmonary function in patients with chronic obstructive pulmonary disease (COPD).

Methods: The Embase and MEDLINE™ databases and the Cochrane Controlled Trials Register were searched comprehensively to identify all relevant clinical trials in humans published between January 1966 and May 2011. Randomized, blinded, placebo-controlled trials that studied the effects of cardioselective β-blockers on the forced expiratory volume in 1 s (FEV(1)) and the responsiveness of the FEV(1) to β-agonist administration in patients with COPD were included in the analysis.

Results: Five studies were identified: four of these assessed both cardioselective and nonselective β-blockers; one assessed only cardioselective β-blockers. The FEV(1) was shown to decrease by 0.14 l with nonselective β-blockers and by 0.03 l with cardioselective β-blockers. The responsiveness of the FEV(1) to β-agonist administration decreased significantly by 13.42% after nonselective β-blockers, but did not change significantly after cardioselective β-blocker administration.

Conclusion: This metaanalysis suggests that the use of β-blockers, especially cardioselective β-blockers, should not be contraindicated in patients with COPD.

Similar articles

See all similar articles

Cited by 10 PubMed Central articles

See all "Cited by" articles

Publication types

MeSH terms

Substances

LinkOut - more resources

Feedback